{"entity":{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","aka":[],"tldr":"A phase 1/2 trial of Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Wayshine Biopharm, Inc., now recruiting.","summary":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC is a phase 1/2 interventional study registered as NCT07206498 by Wayshine Biopharm, Inc., with 48 participants planned, started 2025-10-17 and due to reach its primary completion in 2028-10-14. Interventions recorded: Osimertinib (Tagrisso®), WSD0922-FU. Conditions listed: Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07206498","url":"https://clinicaltrials.gov/study/NCT07206498"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07206498","phase":"1/2","setting":"A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU in Combination With Osimertinib for Patients With Locally Advanced or Metastatic Non- Small Cell Lung Cancer","sponsor":"Wayshine Biopharm, Inc.","enrolled":48,"outcomes":[]},"route":"/trials/nct07206498/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}]}}